PedAM
Pediatric Disease Annotations & Medicines
| Disease | c syndrome |
| Phenotype | C0036341|schizophrenia |
| Sentences | 59 |
| PubMedID- 22120854 | Prevalence of diabetes, obesity, and metabolic syndrome in subjects with and without schizophrenia (cures-104). |
| PubMedID- 25034455 | Is abnormal non-high-density lipoprotein cholesterol a gender-specific predictor for metabolic syndrome in patients with schizophrenia taking second-generation antipsychotics. |
| PubMedID- 25917886 | The principal objective of this study was to investigate the relationship between sensory gating deficit and metabolic syndrome in patients with schizophrenia, after adjusting for key confounding factors. |
| PubMedID- 24837425 | Metabolic syndrome is associated with both schizophrenia and antipsychotic medication, especially clozapine, with alterations in inflammatory cytokines and adipokines. |
| PubMedID- 23188979 | [2] found that the age-adjusted prevalence of metabolic syndrome in patients with schizophrenia was 40.9%, based on the criteria from the third report of the national cholesterol education program's expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii) (ncep atp iii). |
| PubMedID- 21772644 | There are limited data on the prevalence of metabolic syndrome in patients with schizophrenia at the onset of the disorder and, specifically, no data on patients treated in the era when only first-generation antipsychotics were available. |
| PubMedID- 23286356 | The present study also adds to the current knowledge that schizophrenia patients with metabolic syndrome do have a decreased health related muscular fitness compared to those without metabolic syndrome. |
| PubMedID- 22503355 | Prevalence of metabolic syndrome in patients with schizophrenia in india. |
| PubMedID- 23882141 | The prevalence of metabolic syndrome in patients with schizophrenia from this study (39% in females, 35% in males) was slightly lower than that reported from the us clinical antipsychotic trials of intervention effectiveness (catie) study, which found the prevalence to be 52% in females and 36% in males, but was higher than the overall rate of 32.5% from a meta-analysis by mitchell et al.22,23 the difference in prevalence might be explained by racial/ethnic heterogeneity, environmental factors, dietary consumption, and the criteria of metabolic syndrome used.24 the higher prevalence of metabolic syndrome in females found in our study was in line with that reported in the catie study22, although the sex difference in this study was not statistically significant. |
| PubMedID- 25762938 | Metabolic syndrome in schizophrenia patients can be partially explained as a side-effect of antipsychotic medications (448). |
| PubMedID- 20425584 | Metabolic syndrome associated with schizophrenia and atypical antipsychotics. |
| PubMedID- 22754543 | Finally, preliminary evidence suggests that folate supplementation, which may restore balance of the aldo met cycle, improves endothelial function in schizophrenia patients with metabolic syndrome (ellingrod et al., 2012). |
| PubMedID- 24891713 | Its effectiveness, both for positive and negative symptom schizophrenia with lower chances of metabolic syndrome, will help psychiatrists to treat schizophrenic and related disorders more effectively. |
| PubMedID- 21994515 | In this cross-sectional study, we investigated whether htr2c-759c/t, htr2c-697g/c, pparα v227a, and pparγ 161c/t genotypes were associated with metabolic syndrome (mets) in patients with schizophrenia taking clozapine. |
| PubMedID- 24955550 | Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study. |
| PubMedID- 22970386 | To improve quality of life and decrease metabolic syndrome in patients with schizophrenia, it is essential for caregivers to support patients' drug administration with a minimal effective dose, and aripiprazole is considered to be one of the most effective options available. |
| PubMedID- 24204153 | Sod2 also plays crucial roles in antioxidant defense mechanisms.31 the val16ala polymorphism has been linked to cardiovascular disease and to type 2 diabetes and its complications in the general population, but studies so far have yielded conflicting results.28,29,33 in the present study, we did not find any significant associations between the sod2 genotype and the risks of being overweight and having metabolic syndrome in patients with schizophrenia or controls. |
| PubMedID- 23960421 | Despite expected controversies, some patient-related risk factors for the development of metabolic syndrome in patients with schizophrenia receiving atypical antipsychotic drugs are found in the literature. |
| PubMedID- 21105277 | The prevalence of the metabolic syndrome is increased in patients with schizophrenia compared with the general population. |
| PubMedID- 25126357 | Objectives: to summarize the current literature on atypical antipsychotic-induced metabolic syndrome in patients with schizophrenia, outline some of the molecular mechanisms behind this syndrome, identify demographic and disease-related risk factors, and describe cost-effective methods for surveillance. |
| PubMedID- 21477998 | Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: findings from the clamors study. |
| PubMedID- 22044502 | Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a german observational study. |
| PubMedID- 24249923 | To help the psychiatrists to focus more on these cardiovascular risks in patients with schizophrenia, the concept of metabolic syndrome (mets) has received a lot of attention in psychiatric literature. |
| PubMedID- 20683849 | The objective of this multinational, cross-sectional, pharmacoepidemiological study was to determine the prevalence of diabetes, lipid disorders, obesity, hypertension and the metabolic syndrome in patients with schizophrenia treated with antipsychotic drugs. |
| PubMedID- 22986004 | schizophrenia is statistically associated with metabolic syndrome, hypertension, and migraine because they form a cluster of diseases with similar pathophysiology. |
| PubMedID- 22796278 | Moreover, strategies to reduce inflammation and obesity may prevent metabolic syndrome in patients with schizophrenia who take atypical antipsychotic medication. |
| PubMedID- 22841467 | [metabolic syndrome in patients with schizophrenia and antipsychotic treatment]. |
| PubMedID- 20923919 | A uk systematic review and meta-analysis examined the relative risk of diabetes, dyslipidaemia, hypertension and metabolic syndrome in people with smi including schizophrenia (osborn et al., 2008). |
| PubMedID- 21791046 | This study aimed to investigate the degree that antipsychotic polypharmacy contributed to metabolic syndrome in outpatients with schizophrenia, after adjustment for the effects of lifestyle. |
| PubMedID- 22541717 | Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. |
| PubMedID- 25568478 | Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit. |
| PubMedID- 22592510 | A possible stratification of the risk of metabolic syndrome in patients with schizophrenia receiving atypical antipsychotic drugs is as follows: minimal-risk societies are constituted by societies living in eastern asian countries, whereas intermediate-risk societies are constituted by societies living in western asia and south america, and high-risk societies are societies living in australia. |
| PubMedID- 22926590 | Higher prevalence rates of metabolic syndrome (mets) in patients with schizophrenia are getting more and more attention. |
| PubMedID- 22869990 | (c)obesity and metabolic syndrome coexist with schizophrenia with or occasionally even without concurrent drug therapy. |
| PubMedID- 24682777 | There is no doubt that antipsychotic treatment is strongly associated with the development of metabolic syndrome in schizophrenia (hasnain et al. |
| PubMedID- 22154487 | [metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake]. |
| PubMedID- 26041435 | Particularly, cognitive impairment, a core symptom of schizophrenia, is associated with metabolic syndrome5758 and chronic inflammation19. |
| PubMedID- 21398211 | In this article i review the theoretical and practical aspects of the comorbidity of schizophrenia with metabolic syndrome and diabetes mellitus. |
| PubMedID- 20850274 | Prevalence of metabolic syndrome among patients with schizophrenia in japan. |
| PubMedID- 22438935 | In patients suffering from schizophrenia, a high incidence of metabolic syndrome or coronary heart disease (chd) have frequently been reported [1], [2]. |
| PubMedID- 26093599 | [the stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial]. |
| PubMedID- 23153955 | The aetiology of the metabolic syndrome in schizophrenia is multi-factorial and may involve antipsychotic treatment, high levels of stress and unhealthy lifestyle, such as poor diet. |
| PubMedID- 26090224 | The prevalence of metabolic syndrome among individuals with schizophrenia varied between 19 and 29%, depending on the measurement criteria [66, 67], and 45% had insulin resistance [68]. |
| PubMedID- 23138143 | Prevalence of metabolic syndrome among patients with schizophrenia in singapore. |
| PubMedID- PMC2945179 | The prevalence of metabolic syndrome among people with schizophrenia was 36.6% in men and 54.2% in women (21), far above the levels of 25.1% and 19.7%, respectively, in the overall u.s. population. |
| PubMedID- 26001844 | It has been estimated that the prevalence of metabolic syndrome in patients with schizophrenia may be as high as one in three [7]. |
| PubMedID- 21185157 | Association between htr2c polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics. |
| PubMedID- 25878665 | The rate of metabolic syndrome and diabetes in patients with schizophrenia is higher than the general population. |
| PubMedID- 23528272 | In people with schizophrenia, rates of obesity and the metabolic syndrome are high compared to the general population. |
| PubMedID- 23337566 | Conclusion: the prevalence of metabolic syndrome in schizophrenia patients receiving antipsychotic monotherapy in malaysia was very high. |
Page: 1 2